TEMPEST THERAPEUTICS INC. - COMMON STOCK

Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting

08 Apr 2022 13:00:00 By Nasdaq GlobeNewswire

Tempest Reports Year End 2021 Financial Results and Provides Business Update

29 Mar 2022 16:00:00 By Nasdaq GlobeNewswire

Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference

10 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

08 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference

09 Feb 2022 08:00:03 By Nasdaq GlobeNewswire

Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab

18 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer

12 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights

10 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

Tempest to Present at Two Upcoming Investor Conferences in November

09 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495

08 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

01 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche

20 Sep 2021 08:00:02 By Nasdaq GlobeNewswire

Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target

13 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Tempest to Present at Upcoming Investor Conferences

09 Sep 2021 16:01:00 By Nasdaq GlobeNewswire